

Comments On the Consultation Paper

1、 Section 74(e)

The durable patents shall include exclusive patent license in relation to its Core Product(s).

2、 Section 84

It would be better if the shares subscribed by cornerstone investors will be counted towards determining whether the Biotech Company has met the minimum initial public float requirement.

3、 Section 92

If the listed Biotech Companies reach one of the Financial Eligibility Tests in the future, can the unique stock marker “B” be removed from the end of their stock name?

4、 Trading Record of Biotech Companies

Followed practice adopted by NSDAQ, a shorter trading record period say not less than two financial years should be acceptable for a Biotech Company to be listed under Biotech chapter, if the Biotech Company has been in operation in its current line of business for at least two financial years prior to listing under substantially the same management.